logo

For the Inventor, By the Inventor

Zug, Switzerland

Baxalta Gmbh


USPTO Granted Patents = 153

% Expired Patents = 17.0



Trademarks = 2

Forward Citations = 501

Loading Chart...
Loading Chart...

235 inventors (with patents filed for the assignee):

goldMedal Hans-Peter Schwarz (58 out of 107 patents)

silverMedal Manfred Reiter (54 out of 71 patents)

bronzeMedal Peter Turecek (52 out of 120 patents)

4.  Friedrich Scheiflinger (46 out of 76 patents)

5.  Leopold Grillberger (46 out of 42 patents)

6.  Hanspeter Rottensteiner (34 out of 35 patents)

7.  Wolfgang Mundt (32 out of 63 patents)

8.  Wolfgang Teschner (30 out of 35 patents)

9.  Michael Dockal (30 out of 31 patents)

10.  Meinhard Hasslacher (29 out of 35 patents)

11.  Artur Mitterer (23 out of 53 patents)

12.  Alfred Weber (20 out of 28 patents)

13.  Juergen Siekmann (20 out of 45 patents)

14.  Friedrich Dorner (18 out of 91 patents)

15.  Harald Arno Butterweck (16 out of 18 patents)


Core Competencies:
Factor VIII
ADAMTS13
von Willebrand Factor
Biologically Active Peptides
Gene Therapy
Protein Purification
Chromatographic Methods
Hemophilia
Cell Culture
Immunoglobulin G
TFPI Inhibitors
Nucleophilic Catalysts

153 patents:

1. 12622950 - TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF (2026-05-12),
2. 11305000 - Chimeric OspA genes, proteins and methods of use thereof (2022-04-19),
3. 11081211 - Method and apparatus for providing a pharmacokinetic drug dosing regimen (2021-08-03),
4. 11020459 - Factor VIII formulations (2021-06-01),
5. 10934340 - Separation of VWF and VWF propeptide by chromatographic methods (2021-03-02),
6. 10905746 - Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF (2021-02-02),
7. 10900979 - Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD) (2021-01-26),
8. 10875906 - Removal of serine proteases by treatment with finely divided silicon dioxide (2020-12-29),
9. 10842853 - Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia B (2020-11-24),
10. 10822394 - Method of producing recombinant high molecular weight vWF in cell culture (2020-11-03),
11. 10822376 - Biologically active peptides (2020-11-03),
12. D898342 - Carrying case (2020-10-13),
13. 10800816 - TFPI inhibitors and methods of use (2020-10-13),
14. 10772968 - Glycopolysialylation of non-blood coagulation proteins (2020-09-15),
15. 10758599 - Stabilized liquid and lyophilized ADAMTS13 formulations (2020-09-01),
Baxalta GmbH is a global biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare and chronic diseases. With a focus on improving patients' lives, Baxalta discovers, manufactures, and markets a wide range of biologic medicines, vaccines, and hematology products. They are dedicated to advancing science and finding innovative solutions to address unmet medical needs around the world.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Baxalta Gmbh
153 Patents

#7 in Zug

#119 in Switzerland

#5,322 in the World

Zug, CH
Zug, Switzerland

Baxalta Gmbh

Forward Citations = 501

235 inventors:

goldMedal Hans-Peter Schwarz (58 out of 107 patents)

silverMedal Manfred Reiter (54 out of 71 patents)

bronzeMedal Peter Turecek (52 out of 120 patents)

4.  Friedrich Scheiflinger (46 out of 76 patents)

5.  Leopold Grillberger (46 out of 42 patents)

Please report any incorrect information to [email protected]
Loading…